OBJECTIVE: To probe into the application of antiviral drugs in patients with COVID-19

so as to provide references for the rational application of antiviral drugs in COVID-19 patients.METHODS: Retrospective research was adopted to analyze the basic information and application of antiviral drugs of 51 patients with COVID-19 discharged from the Infectious Disease Hospital of Heilongjiang Province（ hereinafter referred to as "our hospital"）from Feb.4 th

2020 to Mar.16 th

2020.RESULTS: Among the 51 patients with COVID-19

27 cases were male（ 52.94%）

24 cases were female（ 47.06%）

with similar percentages; aged from 2-81 years old

disease occurred in all age groups

mostly were middle-age and elderly people; with the average length of stay was（ 20.76±7.46） days;the time of testing negative conversion of nucleic acid of severe acute respiratory syndrome coronavirus 2（ SARS-CoV-2） was 5-35 days

with an average of（ 18.00±7.07） days; all the 51 patients had been treated with antiviral drugs

of which 49 cases were given arbidol

37 cases were given lopinavir/ritonavir

50 cases were given interferon-α

11 cases were given ribavirin injection

2 cases was given Oseltamivir phosphate capsule

17 cases were given hydroxychloroquine sulfate; the therapeutic regimen was mainly three-drug combination of arbidol

lopinavir/ritonavir and interferon-α

very few patients was given four-drug combination.CONCLUSIONS: The application of antiviral drugs is basically rational in patients with COVID-19 in our hospital

with individualized diagnosis and treatment scheme

while there are also cases applied more than three-drug combination in individual patients

which needs more attention on its safety and rationality.